Preclinical Profile and Characterization of the Hepatitis C Virus NS3 Protease Inhibitor Asunaprevir (BMS-650032)Fiona McPhee, Paul M. Scola, Michael Sinz et al.|Antimicrobial Agents and Chemotherapy|2012Cited by 186
The Discovery of Asunaprevir (BMS-650032), An Orally Efficacious NS3 Protease Inhibitor for the Treatment of Hepatitis C Virus InfectionPaul M. Scola, Jialong Zhu, Li‐Qiang Sun et al.|Journal of Medicinal Chemistry|2014Cited by 112
Discovery of a Hepatitis C Virus NS5B Replicase Palm Site Allosteric Inhibitor (BMS-929075) Advanced to Phase 1 Clinical StudiesKap‐Sun Yeung, John F. Kadow, Brett R. Beno et al.|Journal of Medicinal Chemistry|2017Cited by 31
Discovery of a Potent Acyclic, Tripeptidic, Acyl Sulfonamide Inhibitor of Hepatitis C Virus NS3 Protease as a Back-up to Asunaprevir with the Potential for Once-Daily DosingLi‐Qiang Sun, William Warner, Eric Mull et al.|Journal of Medicinal Chemistry|2016Cited by 31
CCDC 984267: Experimental Crystal Structure DeterminationPaul M. Scola, Fiona McPhee, Li‐Qiang Sun et al.|The Cambridge Structural Database|2014Cited by 0